The Endocannabinoid System

Almost every physiological system was found by studying the body. This one was found by studying a plant. In 1964 Raphael Mechoulam and Yechiel Gaoni isolated Δ9-tetrahydrocannabinol from hashish and finally knew what the active molecule was. The obvious next question took twenty-six years to answer: what does it bind to?

In 1990 that binding site was cloned — a receptor, abundant in the brain, now called CB1. Three years later a second, concentrated in immune tissue, called CB2. And this is the moment the logic reverses. A receptor is not built for a plant. If the human brain is dense with a receptor that cannabis happens to fit, the brain must be making something of its own to fit it.

It was. In 1992 Devane and colleagues, working in Mechoulam's lab, pulled an endogenous ligand out of pig brain and named it anandamide — 아난다마이드 — after the Sanskrit ānanda, bliss. In 1995 came a second and far more abundant one, 2-arachidonoylglycerol, 2-AG.

So the naming is an accident of history. We call them endocannabinoids — 내인성 카나비노이드, endogenous cannabinoids — because we met the plant first. Had the order been reversed, we would call the plant compounds phyto-anandamides, and nobody would think this system had anything to do with cannabis at all. It is worth holding that thought for the whole course: this is your physiology, not a drug's.

내인성 카나비노이드 — 몸이 스스로 만드는 카나비노이드.

The endocannabinoid system is not an organ or a circuit. It is a signalling layer distributed across nearly every tissue — brain, gut, immune cells, bone, skin, liver — and what it does, everywhere, is regulate. It keeps other systems inside their range. The word for that is homeostasis, 항상성, and it is the single most useful frame for everything that follows.

Di Marzo's much-quoted summary of its functions is that it helps you relax, eat, sleep, forget, and protect. That is a mnemonic, not a mechanism — but it captures why a regulatory layer touches appetite, pain, mood, memory and immunity all at once, and why claims that it does everything are simultaneously exaggerated and not entirely wrong.

Which is also the trap. A system that modulates almost everything is irresistible to marketing. Nearly every overreach in this field starts from a true statement about breadth and slides into a false one about efficacy.

The receptor biology is textbook and is marked established. Clinical usefulness is a separate question with a separate answer per condition, and most of it sits at emerging or lower. Where the honest answer is that we do not know, the course says so — that is what the tiers are for, and in a field this commercially noisy it is the most valuable thing I can give you.

References

1. Gaoni, Y. & Mechoulam, R. (1964). Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. Journal of the American Chemical Society, 86(8), 1646–1647.●The isolation of THC — where the whole story starts.
2. Matsuda, L. A. et al. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561–564.●CB1 cloned — the receptor that implied an endogenous ligand.
3. Devane, W. A. et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946–1949.●Anandamide.
4. Di Marzo, V., Bifulco, M. & De Petrocellis, L. (2004). The endocannabinoid system and its therapeutic exploitation. Nature Reviews Drug Discovery, 3, 771–784.●The review behind the homeostatic framing used throughout this course.

CB1 is among the most abundant G-protein-coupled receptors in the brain, concentrated where you would expect given the effects: basal ganglia and cerebellum (movement), hippocampus (memory), cortex, hypothalamus (appetite), and the periaqueductal grey (pain modulation). It is strikingly sparse in the brainstem regions that drive respiration — which is the accepted explanation for why cannabinoid overdose does not stop breathing the way opioid overdose does.

CB2 sits mainly on immune cells and in the periphery — spleen, tonsils, microglia, bone. Broadly, CB1 is the neuromodulatory arm and CB2 the immune-inflammatory arm, though the tidy split is a teaching simplification rather than a boundary.

Most neurotransmitters are packaged in vesicles and waiting. Endocannabinoids are not: they are lipids, cut out of the cell membrane at the moment they are needed, released immediately, and then destroyed. There is no reservoir to deplete and no store to fill.

The consequence matters more than it sounds. A system with no stockpile cannot be topped up by consuming its products, and its tone is set by rates — how fast it is synthesised, how fast it is broken down — rather than by how much of it exists. Almost every plausible-sounding intervention in this field is really a claim about one of those rates.

Here is the structural oddity. Ordinary synaptic transmission goes forward: the presynaptic cell speaks, the postsynaptic cell listens. Endocannabinoid signalling is retrograde — the postsynaptic cell makes the endocannabinoid and sends it back across the synapse, where it binds CB1 on the presynaptic terminal and tells it to release less.

So the listener turns down the speaker. That is a feedback brake, built into the synapse, and it is why the word for this system's job is regulation rather than excitation or inhibition. It does not carry a message; it adjusts the volume of messages already being sent.

If one image survives this course, let it be this one: not an accelerator, a governor.

Two enzymes end the signal. FAAH (fatty acid amide hydrolase) degrades anandamide; MAGL (monoacylglycerol lipase) degrades 2-AG. Because tone is set by rates, these enzymes are as much a part of the system as the receptors, and they are where a great deal of drug development has aimed — the idea being to raise your own endocannabinoid levels rather than introduce a plant agonist.

That approach has a cautionary history attached, and the next lessons come back to it. A brake you tamper with is still a brake.

References

1. Munro, S., Thomas, K. L. & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61–65.●CB2.
2. Mechoulam, R. et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50(1), 83–90.●2-AG — the more abundant of the two principal endocannabinoids.
3. Lu, H.-C. & Mackie, K. (2016). An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry, 79(7), 516–525.●The clearest short review of the parts list and retrograde signalling.

Lesson one told the discovery in three beats. His own slide draws it with more steps between them, and they are worth having in order: 1964, Δ9-THC isolated. 1988, the first pharmacological evidence of a specific cannabinoid binding site in rat brain tissue, via radioligand assay — two years before that receptor was actually cloned. 1990, CB1 cloned. 1992, anandamide isolated. 1993, CB2 cloned. 1995, 2-AG identified, and the word endocannabinoid itself enters use.

1996 closes the loop lesson two describes without dating it: FAAH — the enzyme that ends anandamide's signal — is cloned. By 1996 the system had a receptor, two accepted messengers, and a named off switch, in that order. Discovery followed the logic of the system, not the other way around.

CB1 and CB2 are the classical pair lesson two covers. His slide's full table adds three more groups. Ionotropic: TRPV1 through TRPV4, TRPA1, TRPM8 — heat- and pain-sensing ion channels that several endocannabinoids and phytocannabinoids act on directly, not through CB1/CB2 at all. Novel or 'orphan' G-protein-coupled receptors: GPR3, GPR6, GPR12, GPR18, GPR55, GPR92, GPR119 — still being characterised, several with signalling that doesn't resemble CB1/CB2's. Nuclear receptors: PPARα, PPARγ, PPARδ — which is how cannabinoids reach gene transcription and metabolism, not only fast synaptic signalling.

The table also names non-cannabinoid receptors that endocannabinoids or phytocannabinoids happen to bind anyway: 5-HT1A, 5-HT3, the glycine receptor, adenosine A2A and A3, alpha-2 adrenergic receptors, mu and delta opioid receptors. This is the honest reason isolating 'the' effect of a given cannabinoid is hard — several of them are promiscuous ligands acting on unrelated receptor families at once, and a claim that names only CB1 or CB2 is usually incomplete rather than wrong.

Beyond anandamide and 2-AG, his slide names a peptide class — pepcans, hemopressin-related — and two closely related lipids, PEA (palmitoylethanolamide) and OEA (oleoylethanolamide), structurally similar to anandamide but acting mostly outside CB1/CB2. Further modulators named: N-arachidonoyl amino acids, pregnenolone (which acts as a brake on CB1 signalling specifically, a hormonal buffer rather than a receptor ligand), and lipoxin A4.

Synthesis: DAGLα and DAGLβ make 2-AG; NAPE-PLD makes anandamide; PTPN22 is also listed on the synthesis side. Degradation: MAGL is 2-AG's main route; FAAH1 and FAAH2 handle anandamide; ABHD6 and ABHD12 are secondary routes for 2-AG; NAAA and the COX-2/LOX oxidative pathways are listed as further degradation routes — and COX-2/LOX are also inflammation-signalling enzymes in their own right, which the next lesson's inflammation pathway leans on directly. Transport — how a lipid moves from where it's made to where it acts, and to its own degrading enzyme, without a vesicle to carry it — is the one part of this table his slide names without settling; the mechanism is still an open question, not a gap in this transcription.

Ananda — bliss, in Sanskrit — plus amide, its chemical class. Lesson one already gives the name. What his slide adds is that how much of it you have is not the same for everyone: FAAH activity, which sets how fast anandamide is cleared, varies by a gene variant whose frequency differs by population — his slide cites approximate carrier rates of 21% in European Americans, 14% in East Asians, and 45% in Nigerians. Lower FAAH activity means anandamide clears more slowly, which in the studies behind this figure associates with a higher pain threshold and higher self-reported happiness.

That is a population-level pharmacogenetic finding, not a prediction about any one person, and this course holds it at that tier deliberately — the honest reading is 'this varies by more than lifestyle', not 'your ethnicity determines your baseline mood'.

Lesson two's closing line was that FAAH and MAGL are 'where a great deal of drug development has aimed' — raising your own endocannabinoid levels rather than introducing a plant agonist. His slide's diagram names the two standard research tools for exactly that: JZL184, which blocks MAGL and raises 2-AG, and URB597, which blocks FAAH and raises anandamide. Both are research compounds, not medicines available to write a prescription for, and their place in this lesson is mechanistic, not aspirational.

His slide's brain diagram maps the direction of effect by receptor: through CB1, rising anandamide associates with lower depression, lower pain, lower anxiety — and lower memory, the same trade-off lesson three names as useful forgetting rather than pure deficit. Separately through CB1: higher feeding, higher sleep. Through CB1 and CB2 together: lower neuro-inflammation, the mechanism the next lesson gives a full pathway.

This is the wiring diagram underneath what lesson three already claimed in outline — appetite, pain, memory, mood. Nothing here changes that lesson's tiers; it gives the same claims a specific circuit rather than a general statement of 'the system modulates this'.

References

1. Gaoni, Y. & Mechoulam, R. (1964). Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. Journal of the American Chemical Society, 86(8), 1646–1647.●1964 — already the opening date in lesson one.
2. Devane, W. A., Dysarz, F. A. III, Melvin, L. S., Johnson, M. R. & Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology, 34(5), 605–613.1988 — the radioligand evidence for a cannabinoid binding site, ahead of CB1's cloning.
3. Matsuda, L. A. et al. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561–564.1990 — CB1 cloned, already cited in lesson one.
4. Devane, W. A. et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946–1949.1992 — anandamide, already cited in lesson one.
5. Munro, S., Thomas, K. L. & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61–65.1993 — CB2 cloned, already cited in lesson two.
6. Mechoulam, R. et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50(1), 83–90.1995 — 2-AG, already cited in lesson two.
7. Cravatt, B. F. et al. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 384(6604), 83–87.1996 — FAAH cloned, closing the timeline this lesson adds.

CB1 activation in the hypothalamus and limbic system increases food intake and food reward. This is the least controversial functional claim in the field, and the proof came from the failed reverse: rimonabant, a CB1 blocker, was approved in Europe in 2006 as a weight-loss drug and worked — patients lost weight. It was withdrawn in 2008 because blocking CB1 also produced serious depression and anxiety.

Read that as a physiology lesson rather than a commercial failure. It demonstrated, in humans, that endocannabinoid tone is not a spare knob. Turn it down system-wide and mood goes with it — which tells you the same signalling layer holds appetite and affect in the same hand.

The system is present at every level of pain processing: peripheral nerve terminals, dorsal horn, and the descending modulatory pathways of the midbrain. That endocannabinoids modulate nociception is established physiology.

Whether cannabinoid drugs usefully treat pain in patients is a separate question with a much more cautious answer, and lesson five takes it up properly. Holding those two claims apart is most of what separates a clinician from a brochure.

Hippocampal CB1 activation impairs the formation of new memories — reliably, in animals and people. It is easy to read that as pure deficit, and acutely it is. But a system that dampens encoding is also a system for extinction: letting a learned association fade when it is no longer useful. That is not a failure of memory, it is maintenance of it.

This is the mechanism behind serious research interest in fear extinction and post-traumatic stress. I flag it as emerging, deliberately — the mechanism is sound, the human treatment evidence is early.

Via CB2 on immune cells and microglia, the system modulates cytokine release and inflammatory signalling. Again the direction of effect is regulatory rather than simply suppressive, which is why 'anti-inflammatory' is a poor one-word summary — the same layer can restrain an overshoot or permit a needed response depending on context.

By now the appeal is obvious: one system touching appetite, pain, memory, mood and immunity looks like a master key. But a regulator that reaches everywhere is exactly the thing you cannot push in one place without moving others — rimonabant is that sentence written as a clinical trial.

So the honest reading of breadth is not 'this treats many conditions'. It is 'intervening here has many consequences'. Those are close in wording and opposite in what they ask of a prescriber.

References

1. Christensen, R. et al. (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. The Lancet, 370(9600), 1706–1713.●The meta-analysis that made the psychiatric risk undeniable.
2. Lu, H.-C. & Mackie, K. (2016). An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry, 79(7), 516–525.●Functional distribution across pain, memory and appetite circuits.

His slide draws a body map, not just a list. CB1: concentrated in brain and central nervous system, but also present in peripheral nerves and other organs. CB2: mainly bone, skin, and tissue that interacts with the immune system. TRPV1: blood, bone, bone marrow, tongue, kidney, liver, stomach, and ovaries. TRPV2: concentrated in skin, muscle, kidney, stomach, and lungs. GPR18: mainly bone marrow, spleen, and lymph nodes. GPR55: bone and brain — especially the cerebellum — plus the duodenum and small intestine generally. GPR119: pancreas and the digestive tract.

The receptors the previous lesson named as a taxonomy get a geography here — CB1/CB2 are not the only ones with a mapped distribution, and several of the others sit in tissue neither receptor reaches (bone marrow, cerebellum, pancreas).

His slide's HPA-axis diagram: prefrontal cortex, amygdala and hippocampus signal down through ACTH, the anterior pituitary, and the adrenal cortex, releasing cortisol in a loop that stress activates. Named effects of stress on this system specifically: AEA levels fall, FAAH expression rises, CB1 receptor levels fall. Named consequences: higher pain sensitivity, worse sleep quality, higher anxiety, and lower resilience in recovering from trauma.

Worth stating plainly rather than smoothing over: this is a system meant to buffer stress that is measurably degraded by sustained stress rather than reinforced by it — anandamide tone falls exactly when its regulatory job matters most. His slide's molecular detail adds one more asymmetry: CRH/CRH1 signalling and cortisol rise together with FAAH, while GR and CB1 fall — but 2-AG rises over the same stretch. The two principal endocannabinoids do not move in the same direction under chronic stress, which this lesson states rather than resolves.

Lesson three said the system is 'present at every level of pain processing' without drawing the circuit. His slide does: CB1 reduces pain perception and the biochemical pain response, and separately changes the emotional and conscious component of pain — the same mood/memory territory lesson three and this lesson's earlier section both touch. CB2 acts on peripheral immune cells and on microglia in the central nervous system, modulating the nociceptive response specifically in neuropathic or inflammatory pain.

The pathway itself: ascending pain signal travels periphery to thalamus to cortex/limbic system, and CB1R at the thalamus inhibits that ascending transmission while also shaping how the cortex and limbic system interpret it emotionally. A separate, descending route runs the other way — CB1R activates inhibitory signalling through the periaqueductal grey and the nucleus raphe magnus, which reaches back down to the periphery, where CB2R inhibits neuronal sensitisation and ascending transmission at the source.

CB2 activation reduces inflammation; acute and chronic inflammation both drive pain, which is why this lesson and the previous one sit next to each other on his slide. He names this pathway as a lead into non-communicable disease broadly — cancer, liver disease, cardiovascular disease — rather than a treatment claim for any one of them.

Two routes, per his diagram. Peripherally, cannabinoids act on macrophages and B-cells through TRPV1, CB2 and GPR55, lowering COX-2, iNOS and TNF-α. Centrally, CB2 in the brain acts partly through PPARγ, lowering AKT/ERK/NF-κB/iNOS signalling and lipid peroxidation. Both routes converge on the same two outcomes: fewer inflammatory cytokines, less inflammation overall — one more instance of a signalling layer reaching nearly every tissue, the frame lesson one opened with.

His slide's own name for it, typo included: CECD, Clinical EndoCannabinoid Defiency, proposed by Dr. Ethan Russo. The hypothesis: that chronic underperformance of the endocannabinoid system itself may contribute to a cluster of otherwise unrelated, treatment-resistant conditions — his slide names migraine, fibromyalgia and depression among them. The proposed mechanism runs through the same genetics as the anandamide lesson: FAAH and MAGL gene variants, where lower FAAH activity associates with a higher pain threshold and higher self-reported happiness, and variant frequency differs by population.

His slide's closing line, transcribed as far as it is legible on screen: phytocannabinoids such as CBD and THC are proposed to support a deficient system through FABP — fatty-acid-binding proteins, which ferry endocannabinoids toward the enzymes that degrade them — and through direct CB-receptor activity. The rest of that sentence runs off the visible slide and is not completed here.

CECD is a research hypothesis with a named proposer and a proposed mechanism, not a diagnosis anyone can be tested for and given today. This lesson names it because his slide does; it is not a claim that any named condition is caused by it, and it is not treatment guidance.

References

1. Crowe, M. S. et al. (2014). The endocannabinoid system modulates stress, emotionality, and inflammation. Brain, Behavior, and Immunity.●The endocannabinoid system's documented role in stress and inflammation, matching this lesson's HPA-axis and inflammation sections.
2. Russo, E. B. (2004). Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinology Letters.◗The CECD hypothesis itself, naming the same conditions his slide does.

THC binds CB1 as a partial agonist — it activates the receptor, but less completely than the body's own 2-AG would at full occupancy. Two things follow. It produces effects broadly like an endocannabinoid surge but blunter and far longer-lasting, because it is not cleared by FAAH or MAGL on the timescale your own messengers are. And its dose–response is not a straight line: more is not reliably more, and past a point the anxiolytic becomes anxiogenic.

The long half-life is the part most often missed. Your own system signals in seconds, locally, and then destroys the messenger. An inhaled plant agonist occupies the same receptors for hours, everywhere at once. Same receptor; entirely different pattern of use.

Cannabidiol is where careless teaching does the most damage. CBD has very low affinity for CB1 — it is not 'the calm one at the same receptor'. Its documented actions are elsewhere: it is a negative allosteric modulator at CB1 (it changes how other ligands act there rather than activating it), and it interacts with TRPV1, 5-HT1A, adenosine signalling, and FAAH activity among others.

So when someone tells you CBD works 'through the endocannabinoid system', ask which part. Sometimes the answer is real; often the phrase is doing the work that evidence should.

The term comes from a 1998 paper by Ben-Shabat, Mechoulam and colleagues, describing inactive lipids that enhanced 2-AG activity. It was later extended by Ethan Russo into a broader hypothesis: that whole-plant preparations, with their minor cannabinoids and terpenes, act differently from isolated THC.

The hypothesis is plausible and partly supported in preclinical work. It is also the single most commercially useful claim in the industry, which is precisely why it needs its tier stated out loud. Marked emerging: real research, genuinely open, routinely sold as though it were established.

A product label reporting a high THC percentage is telling you about concentration, not about clinical usefulness, and not about whether the effect you want will arrive. Pharmacologically these are separate axes — affinity, efficacy, dose, route, and the state of the system you are acting on. Conflating them is the most common error in consumer conversation about this plant, and it is worth being able to explain the difference in one sentence.

References

1. Ben-Shabat, S. et al. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology, 353(1), 23–31.●Where the term originates — narrower than its current usage.
2. Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.◗The broad hypothesis, cited as hypothesis.
3. Laprairie, R. B. et al. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology, 172(20), 4790–4805.●Why CBD is not simply a CB1 agonist.

Every major phytocannabinoid starts from the same molecule: cannabigerolic acid, CBGA. Three separate synthase enzymes compete for it inside the plant's resin glands (trichomes), each converting it down a different branch — THCA synthase toward THCA, CBDA synthase toward CBDA, CBCA synthase toward CBCA. Which enzymes a given cannabis strain expresses, and how much, is what actually determines whether it grows into a THC-dominant, CBD-dominant, or balanced plant — a matter of enzyme genetics, not separate chemistry for each cannabinoid.

THCA, CBDA and CBCA — the forms the plant actually makes — are not the active molecules most people are after. Each carries an extra carboxyl group that blocks it from binding its target the way the neutral form does. Heat, or more slowly light and time, knocks that group off as CO2 — decarboxylation — and only then does THCA become THC, CBDA become CBD, CBCA become CBC. This is why raw cannabis eaten straight off the plant is essentially non-intoxicating: smoking, vaporizing, or baking before eating is what does the chemistry a lighter or an oven would otherwise be given no credit for.

THC is not a stable endpoint. Exposed to oxygen, heat and light over time, it oxidizes into cannabinol (CBN) — which is why older, poorly stored cannabis is reported as more sedating and less potent: CBN binds CB1 far more weakly than THC. THC can also isomerize into D8-THC, a milder, less common analogue.

Inside the body, the liver does its own version of this chemistry. THC is first hydroxylated into 11-OH-THC — itself active, and the main reason edibles feel different from smoking: oral THC passes through the liver before reaching circulation, so a meaningfully larger fraction becomes this stronger, slower, longer-lasting metabolite than when THC is inhaled. 11-OH-THC is then oxidized further into 11-nor-9-carboxy-THC (THC-COOH), which is not psychoactive but is fat-soluble and slow to clear — the metabolite standard urine drug screens actually detect, sometimes for weeks after last use in regular users.

None of this chemistry exists for a human's benefit. In the living plant, cannabinoids are reported to serve three defensive roles: THC and CBD absorb ultraviolet light, protecting reproductive tissue high in the canopy; THCA and CBGA are toxic to many insects that would otherwise eat the plant; and THC, CBD, CBG, CBC and CBN together show antimicrobial activity against bacteria and fungi. The plant is not making a drug — it is making sunscreen, insecticide and antiseptic, and a fraction of what it makes also happens to bind receptors in a mammalian nervous system.

The three-word sequence growers use — harvest, dry, cure — is where a plant's chemistry stops changing rapidly and starts to stabilise: drying removes water so the aromatic terpenes and cannabinoids formed during growth aren't lost to rot or evaporation, and curing, a slower controlled aging period, is reported to smooth harshness and shift the balance of what survives. His deck names the sequence without detailing the technique, so that detail stays open.

His slides catalogue the common methods rather than endorsing any: rolled into a joint (in paper) or a blunt (in a tobacco-leaf wrapper), smoked from a pipe, or drawn through a water pipe that cools and filters smoke through water before it's inhaled. Vaporizers heat plant material or concentrate below the point of combustion — some, app-connected, let a user log temperature and dose per session. THCA diamonds — crystallised, near-pure THCA — sit at the potent end of what a pipe or vaporizer can deliver.

Route matters pharmacologically, not just as a matter of preference. Inhaled THC reaches the brain in minutes and clears relatively quickly; swallowed THC is metabolised by the liver first into 11-OH-THC before it reaches circulation — the stronger, slower metabolite the previous lesson covers — which is the chemical reason edibles are reported to feel different, take longer to arrive, and last longer than smoking the same plant.

The oldest methods use only mechanical force or heat. Charas and hashish are made by hand-rubbing or sieving the plant's resin glands off the flower and compressing what collects. Dry sieve or kief is the same trichome material, mechanically separated through a screen rather than by hand. Rosin applies heat and pressure directly to flower or hash, squeezing the resin out with nothing added — no chemical residue to remove afterward, which is the main appeal of this whole category.

Solvent extraction dissolves cannabinoids and terpenes out of the plant material, then removes the solvent, leaving a concentrate behind. Ethanol is polar and pulls chlorophyll and plant pigment along with the cannabinoids, needing more purification afterward; butane and hexane are non-polar and pull a cleaner cannabinoid/terpene fraction, at the cost of being flammable. Supercritical CO2 extraction avoids that trade-off industrially, using pressurised CO2 as the solvent and leaving no residue, but needs equipment far beyond anything done at home.

That last point is worth stating plainly rather than skipping past: home hydrocarbon extraction — running butane through plant material in an enclosed space — is a well-documented cause of fires and explosions, and is illegal in most jurisdictions outside a licensed facility for exactly that reason. Naming that this method exists is not the same as describing how to do it, and this lesson does neither.

His deck names Rick Simpson Oil (RSO) as the case study for cannabis used as medicine: a Canadian who, after a 2003 skin cancer diagnosis, produced his own full-extract cannabis oil — solvent-extracted, retaining the plant's full range of cannabinoids rather than an isolate — and self-reported ingesting a total of 60g over 90 days.

That figure is Rick Simpson's own account of what he did, not a dose this course recommends or a claim this platform has verified. Dr. Kwon's own framing of it: an educational example of cannabis positioned as medicine, not guidance for anyone to follow.

Presented as a historical example only. This site does not verify or endorse the outcome Simpson reported, and offers no dosing guidance of its own — see the disclaimer on every service page.

Three terms do most of the work. Isolate is CBD alone, with every other plant compound removed — the cleanest claim to test, but, per the entourage hypothesis already covered, possibly the least representative of how whole-plant preparations act. Broad-spectrum keeps the other cannabinoids and terpenes but has THC specifically removed or reduced near zero. Full-spectrum keeps everything the extraction pulled out, including trace THC. Which category someone reaches for is usually decided by one practical constraint — a drug test, a legal THC limit — rather than a pharmacological one.

A strain's 'profile' is usually reported as its cannabinoid ratio (THC:CBD, chiefly) plus its dominant terpenes — myrcene, limonene, pinene, caryophyllene and the rest, aromatic compounds found across the plant kingdom, not unique to cannabis. Terpenes are proposed to modulate the plant's overall effect, the mechanism the entourage hypothesis names, and at least one — caryophyllene — binds CB2 directly rather than merely accompanying THC and CBD.

Strain names themselves, 'indica', 'sativa', a proprietary name, are marketing categories, not verified chemotypes: two products sold under the same strain name can differ meaningfully in actual lab-tested content. A certificate of analysis, not a name, is what shows what is actually in a product.

CB-receptor activity isn't unique to the cannabis plant. Structurally unrelated compounds in other plants, and even in truffles, interact with the same receptor system — see the earlier lesson's references on plant-derived ligands and truffle-derived anandamide. None of these are marketed as 'cannabinoids' the way cannabis-derived ones are, but pharmacologically the receptor doesn't know the difference.

Synthetic cannabinoids, sold under names like 'K2' or 'Spice' and designed to mimic THC's effect on CB1, are pharmacologically distinct in a way that matters clinically: many act as full agonists at CB1, considerably more potent and less predictable than THC's partial agonism, with no natural ceiling on the effect. They are also frequently reformulated to stay ahead of drug scheduling, so any given batch's exact chemistry, dose and contaminants are often genuinely unknown even to the person selling it. Emergency-department reports connect them to seizures, acute kidney injury, psychosis and deaths not typically seen with plant cannabis at comparable use levels. This is not a stronger version of the same drug; it is a different pharmacological category that happens to target the same receptor.

References

1. Gertsch, J. et al. (2008). Beta-caryophyllene is a dietary cannabinoid. PNAS, 105(26), 9099–9104.●Caryophyllene binding CB2 directly, the exception to terpenes as mere accompaniment.
2. Woelkart, K. et al. (2008). CB receptor ligands from plants. Current Topics in Medicinal Chemistry.Plant-derived CB-receptor ligands outside cannabis.
3. Pacioni, G. et al. (2015). Truffles contain endocannabinoid metabolic enzymes and anandamide. Phytochemistry.Truffle-derived anandamide and its metabolic enzymes.
4. Trecki, J., Gerona, R. R. & Schwartz, M. D. (2015). Synthetic Cannabinoid-Related Illnesses and Deaths. New England Journal of Medicine, 373(2), 103–107.●Synthetic-cannabinoid illness and death reports.

Inhalation — smoking, vaporizing — gives the fastest onset, cannabinoids crossing from lung to bloodstream in seconds to minutes, and the shortest duration, since blood levels peak and fall quickly. Oral ingestion is the opposite: absorption is slow and unpredictable (30–90 minutes to onset, longer with food), but because it passes through the liver first, more of it converts to 11-OH-THC — the stronger, longer-lasting metabolite the earlier lesson on plant chemistry covers — which is why edibles are reported as more intense and much longer-lasting per equivalent dose. Sublingual and buccal routes, absorbed under the tongue or against the cheek, sit between the two: faster than swallowing, without full first-pass metabolism, though a portion is still swallowed and processed the slow way regardless.

Topical and transdermal routes are different again: applied to skin, cannabinoids are highly lipophilic and penetrate slowly, and most topical products are formulated for local effect only. Meaningful systemic absorption generally requires a transdermal-specific delivery system — a patch, a penetration enhancer — not a standard lotion.

THC is highly lipophilic and distributes into fat, redistributing there over hours to days — the mechanistic reason THC and its metabolites remain detectable in regular users for weeks after last use, long after any subjective effect has ended: it is being slowly released back out of fat stores rather than lingering in blood. It also binds plasma proteins heavily, largely albumin and lipoproteins, which limits how much circulates freely at any moment.

Cannabinoid metabolites clear mainly through two routes: roughly two-thirds via faeces (biliary excretion) and about a third via urine, in most pharmacokinetic studies. The inactive metabolite THC-COOH, covered in the lesson on plant chemistry, is what standard urine immunoassays actually screen for, not THC itself — which is why detection windows reflect fat-stored metabolite clearance rather than how long someone felt an effect.

Cannabis law varies sharply by country and changes often — confirmed directly rather than assumed: the same recording this lecture is drawn from is now years old, and its legal-status content would already be out of date if repeated here as fact. A course that states the law wrongly is worse than one that says 'check where you stand', which is this course's own rule from the start.

His own slide makes the same choice for the same reason: rather than asserting a jurisdiction-by-jurisdiction summary, it points to Wikipedia's continuously updated Legality of cannabis page. That page is not a source this platform is deferring to for lack of a better one — it is the honest answer to a question whose true answer changes faster than a course can be re-recorded.

References

1. Wikipedia contributors (2022). Legality of cannabis. Wikipedia, The Free Encyclopedia.SourceHis own lecture's source for this section — a living page, cited so a reader always sees current status rather than a frozen one.

Severe childhood epilepsies. Pharmaceutical-grade cannabidiol reduced convulsive seizure frequency in Dravet syndrome and Lennox-Gastaut syndrome in randomised, placebo-controlled trials, and is licensed for them. This is the strongest evidence in the field, and it is worth noting what made it strong: a purified single molecule, a defined dose, a hard endpoint, and a placebo arm.

Chemotherapy-induced nausea and vomiting. Synthetic cannabinoid antiemetics have decades of use for this indication.

Spasticity in multiple sclerosis. A THC:CBD oromucosal spray is licensed in a number of countries, with modest effect sizes that are real and not large.

Chronic non-cancer pain is the largest use in practice and the most contested in evidence. The 2015 JAMA systematic review found only moderate-quality evidence for chronic pain and spasticity, and low-quality evidence for most other indications; the 2017 US National Academies report reached a similar shape. Neither says cannabinoids do not help pain. Both say the evidence is thinner than the enthusiasm.

Also here: anxiety, sleep, post-traumatic stress, inflammatory bowel disease, appetite in wasting syndromes. Signals exist. Trials are frequently small, short, unblinded — cannabinoids are notoriously hard to blind — or industry-linked. Emerging is the honest label, and it is not a dismissal.

A physician who lists only benefits has stopped practising medicine. Cannabis use disorder is real and more common with early onset, high potency and frequent use. Psychosis risk is consistently associated with heavy use of high-potency products, with adolescent exposure carrying the strongest association — causality remains debated, the association does not. Cognitive effects on attention and memory are acute and reliable; adolescent trajectories are the live research question. Cannabinoid hyperemesis syndrome — cyclical vomiting in long-term heavy users, relieved by hot showers and by stopping — is under-recognised and frequently misdiagnosed for years. Interactions: CBD inhibits cytochrome P450 enzymes and will raise levels of some other drugs, which is exactly the kind of quiet, serious problem that supplement-shaped thinking misses.

Four questions handle most of it. Was it a defined molecule at a defined dose, or a plant product of unknown composition? Was there a placebo arm, and could anyone plausibly be blinded? Was the endpoint hard, or self-reported over two weeks? And who funded it?

Apply those and the field sorts itself quickly: a small evidence base of genuine strength, a large one of legitimate uncertainty, and a marketing layer far larger than both.

References

1. Devinsky, O. et al. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine, 376, 2011–2020.●The strongest trial evidence in the field.
2. Whiting, P. F. et al. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456–2473.●Moderate-quality evidence for pain and spasticity; low for most else.
3. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.●The most comprehensive evidence audit available; used here for both benefits and harms.
4. Allen, J. H. et al. (2004). Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut, 53(11), 1566–1570.●The original description of a syndrome still routinely missed.
5. Moore, T. H. M. et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. The Lancet, 370(9584), 319–328.●The association that any honest course must state.

His slide's THC entry names the same partial-agonist mechanism e4 covers, plus a specific effect list: pain relief, relaxation, improved insomnia, appetite increase, muscle spasm relief, and an antidepressant effect. Its CBD entry frames CBD's action at CB1/CB2 as antagonist rather than e4's negative-allosteric-modulator framing — the two descriptions point at the same low-affinity, non-activating relationship to the receptor, worded differently — and adds a specific effect list of its own: relief of chronic pain from muscle stiffness, spasm and inflammation; symptom relief in multiple sclerosis, fibromyalgia and epilepsy; effective improvement in anxiety-related disorders; and, injected alongside THC, suppressed cancer-cell growth in breast cancer and brain tumours specifically.

That last claim, and several of the others, are clinical outcomes rather than receptor pharmacology, and this lesson is not the place they get evaluated — see e5's clinical ledger and the tiers it already applies to CBD's strongest evidence (Dravet and Lennox-Gastaut) versus its weaker ones. Named here because it's what his slide says, not asserted as this platform's own clinical claim.

This section names his slide's content; it does not re-argue e4's tiers. Where the two frame the same mechanism differently — antagonist versus negative allosteric modulator — that is a difference in how plainly to state a low-affinity interaction, not a factual disagreement.

His slide lists cannabichromene as non-psychoactive, with an antidepressant effect, an ability to enhance THC's own pain relief, a sedative effect that promotes relaxation, promotion of nerve regeneration, antibacterial and antifungal action, and — matching what published pharmacology already says about CBC's weak affinity for CB1/CB2 — action at non-cannabinoid receptors specifically.

Cannabigerolic acid (CBGA) is the precursor the biosynthesis lesson traced into THCA, CBDA and CBCA — but not all of it converts, and what remains becomes CBG. His slide names it non-psychoactive, with pain relief and anti-inflammatory effect, a pressure-lowering effect relevant to glaucoma specifically, an antibiotic role, a neuroprotective role, and — the one receptor mechanism his slide states plainly — CB1 antagonist.

His slide names tetrahydrocannabivarin for appetite suppression and metabolic regulation, memory enhancement and calm, antibacterial and antiviral action, and immune-system support — and gives it a receptor profile split by target: CB1 antagonist, CB2 partial agonist. Published pharmacology adds one further wrinkle his slide doesn't state: at higher doses THCV can act as a partial agonist at CB1 too, the opposite direction from its low-dose antagonism — worth knowing, but that dose-dependent switch is this lesson's addition, not his slide's.

His slide names bone-growth promotion, an analgesic and antispasmodic effect, an anxiolytic effect, and sedation alongside anxiety improvement, with a receptor profile of CB1 and CB2 agonist — not antagonist, unlike CBG and THCV above. What it doesn't restate is the point the biosynthesis and degradation lesson already made: cannabinol isn't synthesised directly by the plant in any quantity, but forms as THC oxidises with age, heat and light, and binds CB1 far more weakly than THC does — the pharmacological reason aged cannabis is widely reported as more sedating and less intoxicating. The popular claim that CBN specifically drives sleep still has more anecdote behind it than trial evidence.

References

1. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V. & Mechoulam, R. (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences.◗The likely source of a pie-chart figure his slide reproduces, grouping effects by CBD/CBDV/THCA/CBC/CBG/THCV — matched by the figure's own journal watermark and cannabinoid lineup, not independently confirmed.

Everything below is transcribed from slides in his own lecture, reproducing published mechanism diagrams and a list of conditions the cannabinoid literature has studied. It is corpus in the same sense s7-s10 are: his own teaching material, edited for the screen, not invented. It is not this platform's clinical claim about any named condition, and nothing here is instruction to use a cannabinoid for anything. The disclaimer on every page of this site — nothing here diagnoses or treats a condition — applies to this lesson at least as much as any other, and more literally than most.

His slide reproduces a published diagram (matching Fernández-Ruiz et al.'s 2015 review, already cited in the reference lesson) centred on 'cannabinoid-based therapies', branching out to six conditions with a proposed mechanism attached to each: Huntington's disease, via CB1/CB2 receptor activation and PPAR/Nrf-2/NF-κB signalling. Alzheimer's disease, via FAAH and MAGL inhibition, CB1/CB2 activation, and the same PPAR/Nrf-2/NF-κB pathway. Stroke and brain trauma, via CBD acting on 5-HT1A receptors, CB1/CB2 activation, and inhibition of endocannabinoid hydrolysis. Parkinson's disease, via CB2 activation, CB1 blockade, and PPAR/Nrf-2/NF-κB signalling. Amyotrophic lateral sclerosis, via FAAH/MAGL inhibition, CB1/CB2 activation, and the same pathway again. Neonatal hypoxia-ischemia, via CBD acting on CB2, 5-HT1A and A2A receptors together.

Six different conditions converging on two or three repeated mechanisms — receptor activation, enzyme inhibition, one recurring signalling pathway — is itself worth noticing: this is a diagram of proposed shared mechanism, not six independent bodies of clinical proof. Fernández-Ruiz et al.'s own title says as much: 'from preclinical models to clinical applications' is a distance, not a completed trip.

A second diagram, on cannabinoids' anticancer action, likely drawn from the same cancer review already cited in the reference lesson (Mangal et al., 2021). It shows THC, CBD, CBG and the endocannabinoids AEA and 2-AG acting on a wider receptor set than this course has named together before: CB1/CB2, TRPV1/TRPV2/TRPM8, and GPR55. Downstream, the diagram traces two convergent routes — de novo ceramide synthesis leading to ER stress and reactive oxygen species, and RhoA/ROCK signalling affecting the actin cytoskeleton — both ultimately reaching the cell's fate machinery: cell-cycle arrest (via p21/p27, blocking proliferation), autophagy, and apoptosis.

This is a mechanism diagram, not a trial result: it shows what cannabinoids are proposed to do to a cancer cell in laboratory models, not what a course of treatment does in a patient. Held at the same tier e5 already gives cancer research generally.

His slide's COVID-19 section — matching the paradigm paper already cited in the reference lesson (Palan et al., 2021) — lists ten proposed mechanisms rather than a diagram: strengthening the endocannabinoid system and regulating ACE2; suppressing inflammatory cytokines; preventing cellular oxidative stress; inhibiting TLR4 (the intracellular signalling pathway responsible for NF-κB activation and inflammatory cytokine production in innate immunity); inhibiting the adenosine A2A receptor, which regulates glutamate and dopamine release; preventing hypoxic damage to brain, lung and heart tissue; preventing bacterial resistance as a complement to antibiotic treatment; stabilising membrane permeability in the lungs; regulating immune-cell migration to the lungs and inhibiting exosome release of virions from infected cells; and improving immune responsiveness through intracellular zinc regulation, by a mechanism his slide states is the same as chloroquine's.

That last point resolves something the reference lesson could not: it cites a 2011 paper on cannabidiol and zinc-homeostasis gene expression in microglial cells, grouped with the COVID-19 references despite predating the pandemic by nearly a decade. His slide's zinc bullet is exactly why — the paper is cited for the zinc mechanism, not for COVID-19 itself, and belongs on this list on that basis rather than by date.

Proposed mechanisms are not a treatment claim. None of this is guidance to use a cannabinoid for COVID-19, and this platform makes none.

The clip closes with a list of conditions grouped by organ system, each paired with a proposed action. Ophthalmological: lowers intraocular pressure — glaucoma. Respiratory: bronchodilation — asthma, COPD. Digestive: antiemetic and improved digestive function — irritable bowel syndrome, Crohn's disease, and reduced side effects with improved efficacy in hepatitis C treatment. Endocrine: metabolic regulation and improved glucose utilisation — obesity, diabetes, metabolic syndrome. Neurological: anticonvulsant, pain relief, anti-inflammatory — epilepsy, Dravet syndrome, Parkinson's disease, multiple sclerosis, cerebral palsy, polio, Alzheimer's/dementia, cerebral haemorrhage, concussion. Psychiatric: antidepressant, anxiolytic, sleep-rhythm restoration — anxiety disorder, depression, insomnia, panic disorder, PTSD, substance addiction. Cancer: suppressing cancer-cell growth and metastasis, pain relief — breast cancer, brain tumour, colon cancer, and mitigating chemotherapy side effects. Joints: pain relief, anti-inflammatory, tissue-regeneration promotion — degenerative arthritis, gout, fracture. Autoimmune disease: immune regulation, anti-inflammatory — psoriasis, lupus, fibromyalgia, coeliac disease, rheumatoid arthritis. Skin: anti-inflammatory, regeneration promotion — wound healing, dermatitis.

His slide continues into a cardiovascular category and a further 'other' category naming menstrual pain among other conditions, but the recording cuts off mid-list at both — transcribed only as far as it is legible, not completed from guesswork.

This is his own slide's survey of what the cannabinoid literature has studied, condition by condition — a scope, not a scorecard. It says nothing about dose, quality of evidence per condition, or whether any individual should act on it, and none of that is supplied here. Read it the way e5 teaches: as raw material for the four questions — defined molecule or plant product, placebo-controlled or not, hard endpoint or self-report, and who funded it — not as a menu.

References

1. Fernández-Ruiz, J. et al. (2015). Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics.◗The likely source of the neurodegenerative-disease diagram his slide reproduces.
2. Mangal, N. et al. (2021). Cannabinoids in the landscape of cancer. Journal of Cancer Research and Clinical Oncology.◗The likely source of the cancer-mechanism diagram his slide reproduces.
3. Palan, N. et al. (2021). The Immunopathology of COVID-19 and the Cannabis Paradigm. Frontiers in Immunology.◗The COVID-19 paradigm paper his slide's ten-point mechanism list draws on.
4. Juknat, A. et al. (2011). Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells. Neurochemistry International.The zinc-homeostasis mechanism behind this slide's chloroquine-comparison bullet — resolves why the reference lesson found it grouped with COVID-19 papers despite predating them.

For decades the euphoria after sustained exercise was attributed to endorphins. The problem is size: endorphins are large peptides and do not readily cross the blood–brain barrier, so the story never quite worked. Endocannabinoids are small lipids that cross easily, and they rise measurably with sustained moderate exercise.

In 2015 Fuss and colleagues closed the loop in mice: block cannabinoid receptors and the running-induced anxiolysis and analgesia disappear. Blocking opioid receptors did not abolish it. The runner's high, at least in that model, depends on this system.

Sustained aerobic exercise raises circulating endocannabinoids most reliably. Dietary fat composition supplies the precursors, since these are lipids built from arachidonic acid. Sleep, stress and social contact all interact with the system in directions that are documented but not simple.

I mark this whole area emerging on purpose. That exercise raises endocannabinoids is established; that you can meaningfully train your endocannabinoid tone as a health strategy, with outcomes that matter, is a reasonable hypothesis wearing a lot of supplement marketing. The distance between those two sentences is the discipline this course is teaching.

It would be easy, and wrong, to claim that breath practice tunes your endocannabinoid system. I am not claiming it. What I will say is narrower and better supported: the practices taught elsewhere on this platform act on autonomic state through pathways that are separately measured — baroreflex coupling, vagal tone, heart-rate variability — and that autonomic state and endocannabinoid signalling are neighbours in the same regulatory neighbourhood.

That is an honest adjacency, not a mechanism. If someone eventually measures 調息 practice against endocannabinoid markers, we will know something we currently do not. Until then this lesson sits at observation, and says so.

항상성 — 몸이 스스로 균형을 유지하는 능력.

The endocannabinoid system is the clearest example on this platform of something the body does quietly, constantly, and without instruction — a governor holding a dozen systems inside their range. The traditions described a regulating principle long before anyone could name a receptor, and they were describing something. What has changed is that part of it is now measurable, and where it is measurable we should say so precisely, and where it is not we should say that too.

That is the whole method, arriving from the biochemical end instead of the contemplative one.

References

1. Fuss, J. et al. (2015). A runner's high depends on cannabinoid receptors in mice. Proceedings of the National Academy of Sciences, 112(42), 13105–13108.●The study that reassigned the runner's high from opioids to this system.
2. Raichlen, D. A. et al. (2012). Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals. Journal of Experimental Biology, 215(8), 1331–1336.●Exercise-induced endocannabinoid rise in humans.

On trichomes as the site of production, and on the biosynthesis pathway covered in the earlier lesson on how the plant builds these molecules.

A narrative review of processing and extraction methods, a paper optimising supercritical CO2 extraction specifically, and an industry explainer on hydrocarbon extraction — named in the earlier lesson on how cannabis is used, without the how-to.

How cannabinoid metabolites interact with the liver's CYP450 enzyme family — relevant to drug interactions, since CYP450 is also how many prescription medications are cleared.

Plant-derived CB-receptor ligands are not unique to cannabis: truffles contain endocannabinoid metabolic enzymes and anandamide itself, and a Korean native plant extract (Dendropanax morbiferus) has been studied for effects on oligodendrocyte development — a reminder that this receptor system predates, and extends well past, the one plant most associated with it.

The paper that found it — Devane, Mechoulam and colleagues' 1992 isolation of the first identified endocannabinoid — alongside a 25-years-later review of its metabolism, a study on its role in stress, emotionality and inflammation, and a New York Times opinion piece his slide cites by URL alone.

On CB1 receptor distribution in the brain and its relevance to drug policy; on stress and the brain's own endocannabinoid tone; and on the system's documented role in pain, by way of the brain-gut axis.

Ethan Russo's clinical endocannabinoid deficiency hypothesis, cannabinoids in the landscape of cancer research, their role in neurodegenerative disease and stroke/brain trauma, two papers connected to COVID-19, and a review of cannabis in gastrointestinal and hepatic disease.

The Cannabis Education Guild (CEG) — an international NGO doing cannabis-related education and consulting, cannabiseducationguild.com, collaborating with the Korean Cannabinoid Association since 2020. Its team, as shown on his slide, includes Dr. Marcus Kwon (his own working name), Dr. Carolina Nocetti, Dr. Ira Price, and Neelan Mohan.

The International College of Cannabinoid Medicine (ICCM) — an online education platform, per his slide, gathering authorities in cannabinoid medicine, iccm.co, under an agreement with the Korean Cannabinoid Association since 2022. His slide also names a 10% discount code (A-KCA-21) tied to that agreement.

Not only an institutional link: he holds seven ICCM CPD certificates himself, completed within twenty days in February 2022 — Overview of Medicinal Cannabis: Foundations, The Endocannabinoid System in Health and Disease, Cannabis Pharmacokinetics, Safety of Medicinal Cannabis, CBD Prescribing Considerations, and Medical Cannabis in Treatment of Chronic Pain, Parts 1 and 2 — the same month the KCA agreement is dated to, and in an order that reads as a full curriculum rather than scattered modules.

References

1. Tanney, C. A. S. et al. (2021). Cannabis Glandular Trichomes: A Metabolite Factory. Frontiers in Plant Science.Cannabis glandular trichomes as the site of cannabinoid production.
2. Tahir, M. N. et al. (2021). The biosynthesis of the cannabinoids. Journal of Cannabis Research.The biosynthesis pathway itself.
3. Lazarjani, M. P. et al. (2021). Processing and extraction methods of medicinal cannabis: a narrative review. Journal of Cannabis Research.Narrative review of processing and extraction methods.
4. Rochfort, S. et al. (2020). Utilisation of Design of Experiments Approach to Optimise Supercritical Fluid Extraction of Medicinal Cannabis. Scientific Reports.Optimising supercritical CO2 extraction specifically.
5. Precision Extraction (2019). What Is Hydrocarbon Extraction? precisionextraction.com.SourceIndustry explainer on hydrocarbon extraction, cited as such — not peer-reviewed evidence.
6. Nasrin, S. et al. (2022). Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Drug Metabolism and Disposition.Cannabinoid metabolites and hepatic CYP450 drug interactions.
7. Zendulka, O. et al. (2016). Cannabinoids and Cytochrome P450 Interactions. Current Drug Metabolism.Cannabinoids and cytochrome P450 interactions generally.
8. Woelkart, K. et al. (2008). CB receptor ligands from plants. Current Topics in Medicinal Chemistry.CB receptor ligands found in plants other than cannabis.
9. Pacioni, G. et al. (2015). Truffles contain endocannabinoid metabolic enzymes and anandamide. Phytochemistry.Truffles containing endocannabinoid metabolic enzymes and anandamide itself.
10. Kim, J.-Y. et al. (2019). Dendropanax morbiferus leaf extract facilitates oligodendrocyte development. Royal Society Open Science.A Korean native plant extract studied for effects on oligodendrocyte development.
11. Devane, W. A. et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946–1949.●The original isolation of anandamide — already cited in an earlier lesson on the system's discovery.
12. Maccarrone, M. (2017). Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years. Frontiers in Molecular Neuroscience.A 25-years-later review of anandamide's metabolism.
13. Crowe, M. S. et al. (2014). The endocannabinoid system modulates stress, emotionality, and inflammation. Brain, Behavior, and Immunity.The endocannabinoid system's role in stress, emotionality and inflammation.
14. The New York Times, Sunday Review, opinion piece (2015-03-08) on genetics and altruism — cited by URL slug ('good-gene') only; title and author are not confirmable from the source slide.Cited by his slide via URL only; title and author not confirmed from the source.
15. Baler, R. D. (2017). Building smart cannabis policy from the… International Journal of Drug Policy.CB1 receptor distribution in the brain, in the context of drug policy.
16. Sharkey, K. A. (2016). The Role of the Endocannabinoid System in the Brain-Gut Axis. Gastroenterology.Stress and the brain's own endocannabinoid tone, via the brain-gut axis.
17. Maldonado, R. (2015). The endocannabinoid system and neuropathic pain. Pain.The endocannabinoid system's documented role in neuropathic pain.
18. Russo, E. B. (2004). Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinology Letters.The clinical endocannabinoid deficiency hypothesis.
19. Mangal, N. et al. (2021). Cannabinoids in the landscape of cancer. Journal of Cancer Research and Clinical Oncology.Cannabinoids in cancer research.
20. Fernández-Ruiz, J. et al. (2015). Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics.Cannabinoids in neurodegenerative disorders and stroke/brain trauma.
21. Juknat, A. et al. (2011). Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells. Neurochemistry International.Grouped with the COVID-19 papers on his slide despite predating COVID-19 by nearly a decade — the reason resolves in the lesson on his indications survey: it's cited for the zinc-homeostasis mechanism, not the disease.
22. Palan, N. et al. (2021). The Immunopathology of COVID-19 and the Cannabis Paradigm. Frontiers in Immunology.The immunopathology of COVID-19 and the cannabis paradigm.
23. Gotfried, J. et al. (2020). Role of Cannabis and Its Derivatives in Gastrointestinal and Hepatic Disease. Reviews and Perspectives: Reviews in Basic and Clinical Gastroenterology and Hepatology.Cannabis and its derivatives in gastrointestinal and hepatic disease.